03-05-2023 : 769 Pharmacists work as Medical Representative, of which 39 work as Senior Medical Representative * 02-06-2020 : 216 non Pharmacists work as Medical Representative, and 54 work as Senior Medical Representative * 05-06-2023 : In Lebanon, 88 generic medicinal products are more expensive than their Originators * 31-12-2019 : A medicinal product refused in Europe is marketed in Lebanon * 05-06-2023 : At least 332 medicinal products are available on the Lebanese market and are not available in the country of origin * 05-06-2023 : The price of the most expensive medicine available in Lebanon is 30434557 LL * 05-06-2023 : At least 1309 medicinal products are more expensive in Lebanon than in the countries of origin * 01-01-2019 : Daktavira, a generic of Daklinza, is registered in Lebanon but has no public price * 31-12-2019 : 352 medicinal products have been declared as non-marketed or withdrawn * 09-11-2021 : 64.72% of lebanese pharmacists are female * 31-12-2019 : 486 medicines were submitted to the Ministry of Health for a marketing authorization, and 514 medicines were registered to date * 15-06-2018 : The Minister of Public Health, has decided to suspend the commercialization of AB Slim (Ab Care Medical Herbs), which contains sibutramine, sildenafil and phenolphthalein * 01-06-2020 : Some Non-Marketed medicines are still imported * 01-06-2020 : Ixempra, a medicinal product withdrawn in Europe is imported to lebanon * 01-06-2020 : A vaccine made in India, removed from WHO list of prequalified vaccines, is submitted for registration in Lebanon * 01-06-2020 : Lebanon has 14 CROs, and is ranked as one of the largest countries in the world in clinical studies. According to the WHO, 817 clinical studies are currently conducted in Lebanon. * 05-01-2021 : * 01-10-2023 : Adakveo is now withdrawn from use in the European Union due to lack of therapeutic efficacy *
Arzerra 1g° : | |
Type | Medicine Withdrawn |
Originator | Biotech (Arzerra 1g) |
Agent | Khalil Fattal & Fils |
Distributor | Khalil Fattal & Fils |
Laboratory | Novartis |
Responsible Party | Novartis Pharma AG |
Origin | Switzerland |
Manufacturer | Glaxo Operations Ltd |
Origin | UK |
ATC | L01XC10 |
Arzerra 1g° :
Arzerra 1g° :
Arzerra 1g° :
Arzerra 1g° :
Arzerra 1g° :
Hazard Level |
---|
◼ Major |
◼ Moderate |
◼ Minor |
◼ Safe |
Arzerra 1g° :
Frequency | Percentage |
---|---|
Very Common | ≥ 1/10 |
Common | ≥ 1/100 - < 1/10 |
Uncommon | ≥ 1/1,000 - < 1/100 |
Rare | ≥ 1/10,000 - < 1/1,000 |
Very Rare | < 1/10,000 |
Unknown | Cannot be Estimated |
Effect | Frequency |
---|---|
Agranulocytosis | Uncommon |
Anaemia | Very Common |
Anaphylactic shock | Uncommon |
Anaphylactoid reactions | Common |
Back pain | Common |
Bacterial infection | Not known |
Bradycardia | Uncommon |
Bronchospasm | Common |
Chest discomfort | Common |
Chills | Common |
Coagulopathy | Uncommon |
Cough | Common |
Cytokine release syndrome | Common |
Diarrhoea (Diarrhea) | Common |
Dyspnoea (dyspnea) | Common |
Fatigue | Common |
Febrile neutropenia (Neutropenic fever) | Common |
Flushing | Common |
Fungal infection | Not known |
Hepatitis B reactivation | Rare |
Herpes virus infection | Common |
Hyperhidrosis | Common |
Hypersensitivity | Common |
Hypertension | Common |
Hypotension | Common |
Hypoxia | Common |
Infusion related reaction | Not known |
Leucopenia (Leukopenia) | Common |
Lower respiratory tract infection | Very Common |
Lymphopenia | Uncommon |
Nasal congestion | Common |
Nausea | Very Common |
Neutropenia | Very Common |
Neutropenic sepsis | Common |
Pharyngolaryngeal pain | Common |
Pneumonia | Very Common |
Pruritus | Common |
Pulmonary oedema | Uncommon |
Pyrexia | Very Common |
Red cell aplasia | Uncommon |
Rigors | Common |
Sepsis (Systemic infection) (Sepsis state) | Common |
Septic shock | Common |
Skin rash | Very Common |
Small intestinal obstruction | Uncommon |
Tachycardia | Common |
Thrombocytopenia (Thrombopenia) | Common |
Tumour lysis syndrome | Uncommon |
Upper respiratory tract infection | Very Common |
Urinary tract infection | Common |
Urticaria | Common |
Viral infection | Not known |
Arzerra 1g° :
NB : Products With Same Indication |
Different Units By MoH Code
Arzerra 1g° MoH 8916 :
Form | Concentrate for solution for infusion |
Packaging | Vial (Type I Glass) |
Package Size | 50ml |
Strength | 1g |
Stratum | N/A |
NSSF | ✘ |
Quarantine | ✘ |
Reg. Number | 154416/1 |
Submission date | 01/01/2016 |
Registration Year | 2017 |
Archived Date | 2018 |
Withdrawn Date | 04/05/2021 |
Price Comparison
● Country: | Abu Dhabi | |
● Package Size: | 50ml | |
● Public Price: | 15498.5 AED | ( 374,459,258.50 LBP ) |
● Pack size unit used: | 1 | |
● Cost/Unit: | 15498,5 AED | ( 374,447,178.00 LBP ) |
● Pharmacy Price: | 13202.5 AED | ( 318985602.5 LBP ) |
● Pricing Date: | 27/01/2021 | |
● Type: | Medicine Authorised |
● Country: | Italy | |
● Package Size: | 50ml | |
● Public Price: | 3591.14 EUR | ( 347,895,278.64 LBP ) |
● Pack size unit used: | 1 | |
● Cost/Unit: | 3591,14 EUR | ( 347,881,716.00 LBP ) |
● Pricing Date: | 17/06/2019 | |
● Type: | Medicine Authorised |
● Country: | Qatar | |
● Package Size: | 50ml | |
● Public Price: | 13913 QAR | ( 341,675,454.00 LBP ) |
● Pack size unit used: | 1 | |
● Cost/Unit: | 13913 QAR | ( 341,675,454.00 LBP ) |
● Pharmacy Price: | 11428.086108426 QAR | ( 280650938.65073 LBP ) |
● Pricing Date: | 28/01/2021 | |
● Type: | Medicine Authorised |
● Country: | Oman | |
● Package Size: | 50ml | |
● Public Price: | 1464.84 OMR | ( 337,988,392.56 LBP ) |
● Pack size unit used: | 1 | |
● Cost/Unit: | 1464,84 OMR | ( 337,794,576.00 LBP ) |
● Pricing Date: | 13/06/2019 | |
● Type: | Medicine Non Marketed |
● Country: | Bahrain | |
● Package Size: | 50ml | |
● Public Price: | 1236.56 BHD | ( 293,972,355.04 LBP ) |
● Pack size unit used: | 1 | |
● Cost/Unit: | 1236,56 BHD | ( 293,839,224.00 LBP ) |
● Reference: | nhra | |
● Pricing Date: | 04/01/2019 | |
● Type: | Medicine Authorised |
● Country: | Finland | |
● Package Size: | 50ml | |
● Public Price: | 2644.96 EUR | ( 256,233,144.96 LBP ) |
● Pack size unit used: | 1 | |
● Cost/Unit: | 2644,96 EUR | ( 256,140,144.00 LBP ) |
● Reference: | Kela | |
● Pricing Date: | 24/10/2020 | |
● Type: | Medicine Non Marketed |
● Country: | KSA | |
● Package Size: | 50ml | |
● Public Price: | 10702.7 SAR | ( 253,011,828.00 LBP ) |
● Pack size unit used: | 1 | |
● Cost/Unit: | 10702,7 SAR | ( 252,995,280.00 LBP ) |
● Reference: | sfda | |
● Pricing Date: | 05/03/2020 | |
● Type: | Medicine Non Marketed |
● Country: | The Netherlands | |
● Package Size: | 50ml | |
● Public Price: | 2524.9 EUR | ( 244,602,212.40 LBP ) |
● Pack size unit used: | 1 | |
● Cost/Unit: | 2524,9 EUR | ( 244,515,024.00 LBP ) |
● Pharmacy Price: | 2517.9 EUR | ( 243924080.4 LBP ) |
● Reference: | Zorginstituut Nederland | |
● Pricing Date: | 15/06/2019 | |
● Type: | Medicine Authorised |
● Country: | Iceland | |
● Package Size: | 50ml | |
● Public Price: | 355350 ISK | ( 229,200,750.00 LBP ) |
● Pack size unit used: | 1 | |
● Cost/Unit: | 355350 ISK | ( 229,200,750.00 LBP ) |
● Pharmacy Price: | 280608 ISK | ( 180992160 LBP ) |
● Reference: | Icelandic Medicines Agency | |
● Pricing Date: | 01/01/2019 | |
● Type: | Medicine Authorised |
● Country: | Spain | |
● Package Size: | 50ml | |
● Public Price: | 2307.67 EUR | ( 223,557,838.92 LBP ) |
● Pack size unit used: | 1 | |
● Cost/Unit: | 2307,67 EUR | ( 223,492,932.00 LBP ) |
● Reference: | Agencia Española de Medicamentos y Productos Sanitarios | |
● Pricing Date: | 04/02/2019 | |
● Type: | Medicine Authorised |
● Country: | Greece | |
● Package Size: | 50ml | |
● Public Price: | 2304.88 EUR | ( 223,287,554.88 LBP ) |
● Pack size unit used: | 1 | |
● Cost/Unit: | 2304,88 EUR | ( 223,202,304.00 LBP ) |
● Exfactory Price: | 1946.316667 EUR | |
● Pharmacy Price: | 1975.51 EUR | ( 191379506.76 LBP ) |
● Reference: | National Organization for Medicines | |
● Pricing Date: | 25/03/2019 | |
● Type: | Medicine Non Marketed |
● Country: | UK | |
● Package Size: | 50ml | |
● Public Price: | 1820 GBP | ( 206,841,180.00 LBP ) |
● Pack size unit used: | 1 | |
● Cost/Unit: | 1820 GBP | ( 206,841,180.00 LBP ) |
● Reference: | DMD | |
● Pricing Date: | 08/03/2021 | |
● Type: | Medicine Withdrawn |
● Country: | Sweden | |
● Package Size: | 50ml | |
● Public Price: | 22723.91 SEK | ( 191,062,635.28 LBP ) |
● Pack size unit used: | 1 | |
● Cost/Unit: | 22723,91 SEK | ( 191,054,984.00 LBP ) |
● Pharmacy Price: | 22233 SEK | ( 186935064 LBP ) |
● Pricing Date: | 08/10/2018 | |
● Type: | Medicine Non Marketed |
● Country: | Norway | |
● Package Size: | 50ml | |
● Public Price: | 22018.4 NOK | ( 178,437,113.60 LBP ) |
● Pack size unit used: | 1 | |
● Cost/Unit: | 22018,4 NOK | ( 178,433,872.00 LBP ) |
● Pharmacy Price: | 17115.06 NOK | ( 138700446.24 LBP ) |
● Reference: | Norwegian Medicine Agency | |
● Pricing Date: | 05/11/2018 | |
● Type: | Medicine Authorised |
● Country: | Denmark |
● Package Size: | 50ml |
● Reference: | Danish Medicine Agency |
● Pricing Date: | 19/05/2021 |
● Type: | Medicine Non Marketed |
● Country: | Portugal |
● Package Size: | 50ml |
● Reference: | Autoridade Nacional do Medicamento e Produtos de Saúde |
● Pricing Date: | 22/04/2019 |
● Country: | Germany |
● Package Size: | 1x50ml |
● Medica Comments: | Not available in the country of origin |
● Pricing Date: | 24/10/2020 |
● Type: | Medicine Non Marketed |
● Country: | France |
● Package Size: | 50ml |
● Reference: | ansm |
● Pricing Date: | 15/05/2021 |
● Type: | Medicine Non Marketed |
Note
You have to register to view this info
Arzerra 1g° MoH 8393 :
Form | Concentrate for solution for infusion |
Packaging | Vial (Type I Glass) |
Package Size | 50ml |
Strength | 1g |
Stratum | N/A |
NSSF | ✘ |
Quarantine | ✘ |
Reg. Number | 186059/13 |
Submission date | 01/01/2013 |
Registration Year | 2016 |
Withdrawn Date | 2017 |
Price Comparison
You have to register to view this info
Drop File